TITLE:
Tofacitinib as a Treatment for Refractory Dermatomyositis: A Case Report
AUTHORS:
Samuel Katsuyuki Shinjo, Fernando Henrique Carlos de Souza
KEYWORDS:
Dermatomyositis, Immunosuppressive Agents, Muscle Diseases, Myositis, Therapeutics
JOURNAL NAME:
Open Journal of Rheumatology and Autoimmune Diseases,
Vol.10 No.1,
February
28,
2020
ABSTRACT: In very scarce case reports and case series, tofacitinib has been a therapeutic alternative for dermatomyositis. To corroborate the literature, we described a refractory dermatomyositis that had a good outcome with tofacitinib. Case Report: An adult female patient presented with definite dermatomyositis and with refractoriness to high doses of intravenous and oral glucocorticoids, intravenous human immunoglobulin, several immunosuppressive drugs (methotrexate, azathioprine, and leflunomide) and two previous immunobiological drugs (rituximab and abatacept). However, the patient had a good outcome with tofacitinib. Conclusions: Tofacitinib appears to be a promising alternative therapy for refractory dermatomyositis.